Table 1.

Patient characteristics

Pat. no.AgeGenderSokal groupEUTOS groupWBC (×106)TreatmentBCR-ABL >10%aMMR month 12Dose intensity (%)Adverse events, gradeConc. med.
143MLRLR28ImaNoNo100Leukopenia, 2No
255FLRLR75ImaNoNo96Leukopenia, 3G-CSF
360FIRLR32DasaNoYes100Anemia, 2No
445MLRLR32DasaNoYes100Leukopenia, 2 Anemia, 1No
551FIRHR40DasaNoYes100NoNo
662MLRLR26ImaNoYes99NoNo
740FLRLR11DasaNoYes100Thrombopenia, 2No
866MLRLR30ImaNoNo100Leukopenia, 2 thrombopenia, 2No
939MLRLR18ImaNoYes100NoNo
1071FIRHR14DasaNoYes100Leukopenia, 2 thrombopenia, 2No
1161FLRLR20DasaNoYes100Anemia, 1NSAID
1252FIRLR109ImaNoNo100Leukopenia, 3G-CSF
1360MHRLR288ImaYesNo100Leukopenia, 2 thrombopenia, 4G-CSF
1463MLRLR22ImaNoNo100NoNo
1544FIRLR164DasaNoYes100Leukopenia, 2No
1645FLRLR39DasaNoYes100NoNo
1773FIRLR45ImaNoYes100NoNo
1847FLRLR46DasaNoYes100Neutropenia, 3G-CSF
1957FLRLR38ImaNoNo100NoNo
2051FLRLR74ImaNoYes100NoNSAID
2171MIRLR37ImaNoYes100Leukopenia, 2No
2258MLRLR43DasaNoMissingb64Pleural effusion, 2G-CSF, steroid
2337MLRLR165ImaYesNo100Neutropenia, 2No
2461MHRHR336DasaNoYes100NoNo
2563FHRLR20DasaNoYes100NoNo
2667FHRHR70ImaNoYes92Leukopenia, 2No
2743MLRLR154ImaNoNo100NoNo
2828FIRLR270DasaNoNo95NoNo
2945FLRLR25DasaNoYes96Leukopenia, 3No
3055MLRLR65ImaNoYes100NoNo
3159FIRLR97ImaYesNo100NoNo
3243MLRLR110ImaYesNo100NoNo

NOTE: Sokal group: LR, low risk (score <0.8); IR, intermediate risk (score 0-8–1-2); HR, high risk (score >1.2). EUTOS group: LR, low risk (score ≤87); HR, high risk (score >87).

Abbreviations: Ima, imatinib; Dasa, dasatinib.

  • aBCR-ABL >10% at month 3; MMR, major molecular response; BCR-ABL is ≤0.1%; grading of adverse events is according to CTCAE.

  • bMMR at 6 months.